MetaADEDB 2.0 @ LMMD
Cyproterone
(DUSHUSLJJMDGTE-ZJPMUUANSA-N)
Structure
SMILES
O=C1C=C2C(=C[C@@H]3[C@@H]([C@]2([C@@H]2[C@H]1C2)C)CC[C@]1([C@H]3CC[C@]1(O)C(=O)C)C)Cl
Molecular Formula:
C22H27ClO3
Molecular Weight:
374.901
Log P:
4.0368
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
1
TPSA:
54.37
CAS Number(s):
2098-66-0
Synonym(s)
1.
Cyproterone
2.
Cyproterone, 1alpha,2 alpha,9 beta,10 alpha-Isomer
External Link(s)
MeSHD003534
PubChem Compound5284537
ChEBI50742
CHEMBLCHEMBL142130
KEGGdr:D07766
ZINC12504523
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal PainCanada Vigilance: 1Canada Vigilance
SIDER
2Abnormal visionSIDER
3Acne VulgarisSIDER
4AcneCanada Vigilance: 1Canada Vigilance
SIDER
5Activated Protein C Resistance15333036CTD
6Acute Coronary SyndromeSIDER
7AgitationSIDER
8Alanine Aminotransferase IncreasedSIDER
9AlopeciaSIDER
10Anemia, Macrocytic9169341CTD
11Anorexia9169341CTD
SIDER
12AphasiaSIDER
13AscitesSIDER
14Aspartate Aminotransferase IncreasedSIDER
15AstheniaSIDER
16AsthmaSIDER
17AzoospermiaSIDER
18BlindnessSIDER
19Blood and lymphatic system disordersSIDER
20Blood cortisol decreasedSIDER
21Blood creatinine increasedSIDER
22Breast tendernessSIDER
23Cerebrovascular accidentSIDER
24ChillsSIDER
25ConstipationSIDER
26Creatinine increasedSIDER
27CrystalluriaSIDER
28CystSIDER
29Depressed moodSIDER
30DermatitisSIDER
31Diabetes MellitusSIDER
32DiscomfortSIDER
33Disturbance in sexual arousalSIDER
34DizzinessSIDER
35Dry skinSIDER
36DyspepsiaSIDER
37EczemaSIDER
38EmbolismSIDER
39EmbolusSIDER
40Erectile dysfunctionSIDER
41Erythema NodosumSIDER
42ExtravasationSIDER
43Familial Testotoxicosis19209621CTD
44FatigueCanada Vigilance: 19169341CTD
SIDER
Canada Vigilance
45Febrile NeutropeniaSIDER
46Feeling abnormalSIDER
47FertilizationSIDER
48Folic Acid Deficiency9169341CTD
49Gastrointestinal PainSIDER
50GlossitisSIDER
51Headache9169341CTD
SIDER
52HemiplegiaSIDER
53Hepatic necrosisSIDER
54HepatitisSIDER
55HepatomegalySIDER
56HepatotoxicitySIDER
57HerniaSIDER
58HirsutismSIDER
59HypersensitivitySIDER
60HyperventilationSIDER
61HypotensionSIDER
62InfertilitySIDER
63Injection Site ReactionSIDER
64LassitudeSIDER
65LeukocytosisSIDER
66LeukopeniaSIDER
67MalaiseCanada Vigilance: 1Canada Vigilance
SIDER
68MalnutritionSIDER
69MeningiomaSIDER
70MenorrhagiaCanada Vigilance: 1Canada Vigilance
71Myocardial InfarctionSIDER
72NauseaSIDER
73Nitrogen balance negativeSIDER
74Nodular regenerative hyperplasiaSIDER
75NoduleSIDER
76Normocytic anemiaSIDER
77Optic AtrophySIDER
78Optic NeuritisSIDER
79OsteoporosisSIDER
80Ovulation inhibitedSIDER
81PainSIDER
82PancreatitisSIDER
83PhlebitisSIDER
84Prostatic Neoplasms15503741CTD
85PruritusSIDER
86Pulmonary EmbolismSIDER
87Pulmonary FibrosisSIDER
88Retinal Vascular DisorderSIDER
89SclerodermaSIDER
90ShockSIDER
91Skin Ulcer9169341CTD
92Sleep Initiation and Maintenance Disorders9169341CTD
93Spermatozoa abnormalSIDER
94SweatingSIDER
95SyncopeSIDER
96Tachycardia9169341CTD
SIDER
97TensionSIDER
98ThrombocytopeniaSIDER
99ThrombophlebitisSIDER
100ThrombosisSIDER
101UrticariaSIDER
102Uterine fibroids enlargedSIDER
103Vaginal DischargeSIDER
104Venous Thromboembolism11705493CTD
105Visual ImpairmentSIDER
106VomitingSIDER
107Weight decreasedSIDER
108jaundiceSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120236

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.